Market Overview:
The global biotinylated polyclonal antibody market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth of the market can be attributed to the increasing demand for biotinylated polyclonal antibodies in research and diagnostic applications. Additionally, the growing prevalence of target diseases is also contributing to the growth of this market. On the basis of type, the global biotinylated polyclonal antibody market can be segmented into primary antibodies and secondary antibodies. The primary antibody segment is expected to account for a larger share of this market in 2018. This segment is projected to grow at a CAGR of 7.8% from 2018 to 2030 owing to its high demand in research and diagnostic applications.
Product Definition:
A biotinylated polyclonal antibody is an antibody that has been labeled with the biotin molecule. The use of biotinylated antibodies allows for the detection of antigens using an enzyme-linked avidin or streptavidin assay.
Primary Antibody:
Primary antibody is the first antibody that is produced in response to a particular antigen. It plays an important role as it binds itself to the antigen and allows other antibodies to attach on its surface. Western blotting is one of the most common techniques used for detecting protein expression using primary antibodies.
Secondary Antibody:
Secondary antibody is also known as the tertiary antibody. It is an antibody that binds to a specific antigen after being exposed to an antigen-antibody complex.
The process of biotinylation involves injecting radiolabeled second antibodies into the patient’s body.
Application Insights:
Western blotting was estimated as largest revenue generating segment in 2017 owing to its wide applications such as drug discovery and clinical diagnostics. Moreover, increasing R&D investments coupled with rising adoption of western blotting for research purposes is anticipated to boost growth during the forecast period.
Immunocytochemistry is expected to be fastest growing sub-segment due largely to its non-invasive nature which makes it highly preferred for detecting cancer cells or viral infection within a tissue sample at an early stage. Furthermore, this technique allows easy detection of multiple targets within a single sample which further boosts growth prospects during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biotechnology companies and significant investments made for R&D are some factors responsible for its continued dominance over the forecast period. In addition, increasing use of btPCA in cancer research is one factor expected to drive regional growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative growth during the same period owing to increasing focus on drug discovery activities by several major pharmaceutical companies coupled with rising investment in life science-related research at universities and institutes. This has resulted into increased adoption of immunological techniques that can be performed using btPCA antibodies, thereby driving regional demand during the forecast period.
Growth Factors:
- Increasing demand for biotinylated polyclonal antibodies from research laboratories for use in a variety of applications such as ELISA, immunohistochemistry, and Western blotting.
- Growing demand for biotinylated polyclonal antibodies from the diagnostic industry for use in point-of-care tests and other medical applications.
- Rising prevalence of various diseases that can be diagnosed through the use of biotinylated polyclonal antibodies.
Scope Of The Report
Report Attributes
Report Details
Report Title
Biotinylated Polyclonal Antibody Market Research Report
By Type
Primary Antibody, Secondary Antibody
By Application
Immunocytochemistry (ICC), Immunoprecipitation (IP), Western Blot (WB), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Immunofluorescence (IF)
By Companies
Merck & Co., Inc, Abcam PLC, PerkinElmer, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Lonza Group, Cell Signalling Technology, Inc, Agilent Technologies, F.Hoffmann La Roche Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
137
Number of Tables & Figures
96
Customization Available
Yes, the report can be customized as per your need.
Global Biotinylated Polyclonal Antibody Market Report Segments:
The global Biotinylated Polyclonal Antibody market is segmented on the basis of:
Types
Primary Antibody, Secondary Antibody
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Immunocytochemistry (ICC), Immunoprecipitation (IP), Western Blot (WB), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Immunofluorescence (IF)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co., Inc
- Abcam PLC
- PerkinElmer, Inc
- Thermo Fisher Scientific
- Bio-Rad Laboratories
- Lonza Group
- Cell Signalling Technology, Inc
- Agilent Technologies
- F.Hoffmann La Roche Ltd
Highlights of The Biotinylated Polyclonal Antibody Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Primary Antibody
- Secondary Antibody
- By Application:
- Immunocytochemistry (ICC)
- Immunoprecipitation (IP)
- Western Blot (WB)
- In Situ Hybridization (ISH)
- Immunohistochemistry (IHC)
- Immunofluorescence (IF)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biotinylated Polyclonal Antibody Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Biotinylated polyclonal antibodies are antibodies that have been biotinylated. This means that a molecule of biotin has been attached to the antibody's amino acid chain. The purpose of this modification is to make it easier for scientists to detect and track the antibody in experiments.
Some of the key players operating in the biotinylated polyclonal antibody market are Merck & Co., Inc, Abcam PLC, PerkinElmer, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Lonza Group, Cell Signalling Technology, Inc, Agilent Technologies, F.Hoffmann La Roche Ltd.
The biotinylated polyclonal antibody market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Biotinylated Polyclonal Antibody Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Biotinylated Polyclonal Antibody Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Biotinylated Polyclonal Antibody Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Biotinylated Polyclonal Antibody Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Biotinylated Polyclonal Antibody Market Size & Forecast, 2020-2028 4.5.1 Biotinylated Polyclonal Antibody Market Size and Y-o-Y Growth 4.5.2 Biotinylated Polyclonal Antibody Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Primary Antibody
5.2.2 Secondary Antibody
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Immunocytochemistry (ICC)
6.2.2 Immunoprecipitation (IP)
6.2.3 Western Blot (WB)
6.2.4 In Situ Hybridization (ISH)
6.2.5 Immunohistochemistry (IHC)
6.2.6 Immunofluorescence (IF)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Biotinylated Polyclonal Antibody Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Biotinylated Polyclonal Antibody Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Primary Antibody
9.6.2 Secondary Antibody
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Immunocytochemistry (ICC)
9.10.2 Immunoprecipitation (IP)
9.10.3 Western Blot (WB)
9.10.4 In Situ Hybridization (ISH)
9.10.5 Immunohistochemistry (IHC)
9.10.6 Immunofluorescence (IF)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Primary Antibody
10.6.2 Secondary Antibody
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Immunocytochemistry (ICC)
10.10.2 Immunoprecipitation (IP)
10.10.3 Western Blot (WB)
10.10.4 In Situ Hybridization (ISH)
10.10.5 Immunohistochemistry (IHC)
10.10.6 Immunofluorescence (IF)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Primary Antibody
11.6.2 Secondary Antibody
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Immunocytochemistry (ICC)
11.10.2 Immunoprecipitation (IP)
11.10.3 Western Blot (WB)
11.10.4 In Situ Hybridization (ISH)
11.10.5 Immunohistochemistry (IHC)
11.10.6 Immunofluorescence (IF)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Primary Antibody
12.6.2 Secondary Antibody
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Immunocytochemistry (ICC)
12.10.2 Immunoprecipitation (IP)
12.10.3 Western Blot (WB)
12.10.4 In Situ Hybridization (ISH)
12.10.5 Immunohistochemistry (IHC)
12.10.6 Immunofluorescence (IF)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Primary Antibody
13.6.2 Secondary Antibody
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Immunocytochemistry (ICC)
13.10.2 Immunoprecipitation (IP)
13.10.3 Western Blot (WB)
13.10.4 In Situ Hybridization (ISH)
13.10.5 Immunohistochemistry (IHC)
13.10.6 Immunofluorescence (IF)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Biotinylated Polyclonal Antibody Market: Competitive Dashboard
14.2 Global Biotinylated Polyclonal Antibody Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck & Co., Inc
14.3.2 Abcam PLC
14.3.3 PerkinElmer, Inc
14.3.4 Thermo Fisher Scientific
14.3.5 Bio-Rad Laboratories
14.3.6 Lonza Group
14.3.7 Cell Signalling Technology, Inc
14.3.8 Agilent Technologies
14.3.9 F.Hoffmann La Roche Ltd